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Technological advances in biology have begun to
dramatically change the way we think about evolution,
development, health and disease. The ability to sequence
the genomes of many individuals within a population, and
acrossmultiple species, has opened the door to the possi-
bility of answering some long-standing and perplexing
questions about our own genetic heritage. One such ques-
tion revolves around the nature of cellular hyperprolifera-
tion. This cellular behavior is used to effect wound healing
in most animals, as well as, in some animals, the regener-
ation of lost body parts. Yet at the same time, cellular
hyperproliferation is the fundamental pathological condi-
tion responsible for cancers in humans. Here, I will discuss
why microevolution, macroevolution and developmental
biology all have to be taken into consideration when inter-
preting studies of both normal and malignant hyperprolif-
eration. I will also illustrate how a synthesis of evolutionary
sciences and developmental biology through the study of
diverse model organisms can inform our understanding
of both health and disease.
Introduction
In the past 40 to 50 years, biologists working on a variety of
organisms have provided the context to understanding
human birth defects and disease. Just as biology is the foun-
dation of medicine, evolution is the foundation of biology.
Thus, evolutionary sciences are in a position to profoundly
inform our understanding of human disease. Take cancer,
for example: cancer does not respect ethnicity, or gender
[1]. That all of us can be potentially fated to experience this
disease speaks to the common thread of genetic ancestry
shared by all humans. This in turn reflects a common gene
toolkit that underlies the complex physiology and body plans
of nearly all animals. In fact, our health and disease states
are but the latest manifestations of the long and ongoing
process of evolution — a combination of random mutation
and drift, natural selection (Box 1), and in the particular
case of humans, even social engineering.
Whether extant or extinct, all organisms share a common
attribute: variation. Such variation represents the collective
genetic history of each population and, in turn, reflects the
evolutionary forces that shaped both the species and the
individuals within each population. Therefore, one must
attempt to understand the extent by which historical evolu-
tionary processes, such as selection and drift, have affected
the mechanistic intricacies of our extant physiological and
pathological states. For example, recent findings for a role
in the regeneration of lost body parts for proteins generally
associated with human cancers [2–4] have prompted a re-
examination of the evolutionary origins of the functions of
these molecules. Resolving the perplexing fact that, despite
possessing a common gene toolkit, origin organisms, suchHoward Hughes Medical Institute and Stowers Institute for Medical
Research, Kansas City, MO 64110, USA.
*E-mail: asa@stowers.orgas planarians, flies, nematodes and many other species, do
not seem to display the same frequency or evidence of
cancer [5] should be of great importance in understanding
the causes/origins and mechanisms of this disease.
As more and more data are being accumulated on the
genomics of cancers [6,7], the functions of so-called ‘cancer
genes’ in diverse, less studied animal species might provide
not only new insights on how the functions of such genes
may have naturally evolved, but also shed light on our mech-
anistic understanding of the disease itself. In this review, I
will attempt to illustrate the need for simultaneously consid-
ering the roles of microevolution, macroevolution (Box 1),
development, and social engineering on biological systems
when interrogating the causes and mechanisms of disease,
particularly those driven by excessive cellular proliferation
such as cancer. I will also suggest that by simultaneously
considering the retrospective nature of evolutionary devel-
opmental biology and the prospective forces of micro-
evolution and population genetics, it becomes possible to
investigate the complexities of present-day human cancers,
and re-examine basic concepts, such as tumor suppression,
aswell as themodel organisms currently being used to study
this and other human disorders.
The Prospective Power of Microevolution
Based on a population of 6 billion people and amutation rate
of 2 3 1028 per base pair, Kruglyak and Nickerson [8] calcu-
lated that, in the most recent human generation, every
possible mutation that is compatible with life will have
occurred an average of 240 times. This rapid rate of change
in the allele frequencies of a population is known as micro-
evolution (Box 1) [9]. That microevolutionary principles can
help explain the incidence, pathology and characteristics
of many human diseases has not gone unnoticed by the
medical community [10–12]. This is particularly evident in
studies in which population genetics have been applied to
uncover the causes of disease susceptibility in human pop-
ulations [13–18]. One intriguing and insightful application
of microevolutionary principles to the study of cancer was
recently put forward by Greaves and Malley [7]. They
describe how the inherent complexity of ‘tissue ecosystems’
in humans provides fertile ground for the appearance of
genetic variation in otherwise clonally identical populations
of cells. This variation effectively leads to rapid rates of
change in allele frequencies in the different cell populations.
In the case of cancers, increase in variation results in the
production of subclones which themselves are subjected
to microevolutionary processes resulting in complex lineage
and branching evolutionary trajectories (Figure 1A). In other
words, it appears as if the ontogeny of some forms of human
cancers can be explained using microevolutionary princi-
ples. At this level of analysis, the appearance of cellular
diversity in tumors is not dissimilar to the appearance of
variation in animal populations (Figure 1B). Consider, for ex-
ample, the wing pattern variation observed in Heliconius —
a butterfly endemic to the tropics of South America — which
is associated with different genomic rearrangements that
lock together distinct genetic elements involved in wing-
pattern formation [19]. Such rearrangements have allowed
Heliconius to generate adaptive wing patterns according to
Box 1
Overview of key evolutionary terms.
Microevolution: changes in gene frequency within a population, which can generally be observed over short periods of time. Such changes
may occur due to at least four different processes:
Mutation: changes in DNA sequence, introduced during DNA replication (cell division).
Natural and/or artificial selection: Natural genetic variants may sometimes be advantageous (positive selection), or deleterious (negative
selection) to the survival and/or reproductive output of an individual, leading to changes in the frequency of genetic variants. This process is
called natural selection. Selection applied by humans to plants and animals [71,72] is called ‘artificial selection’, and can be illustrated by the
remarkable gamut of physical and behavioral features displayed by the more than 350 breeds thus far obtained by pigeon breeders [73].
Genetic drift: As DNA mutates and phenotypic changes are introduced and selected, and variation in the population increases, random
events eventually come into play to determine which genetic changes will be maintained (fixed), or lost from the population. This random
sampling is called genetic drift, and leads over time to changes in the relative frequency of gene variants (alleles) in a given population. In
contrast to natural selection, in which reproductive success makes alleles more or less common, changes introduced by genetic drift are
independent of reproductive or adaptive pressures and thus need not be benign or malignant.
Gene flow: Another force affecting microevolution is gene flow, i.e., the addition or removal of gene variation by either immigration or
emigration of individuals to and from a population. Consequently, migrations can have marked effects on allele frequency by modulating the
genetic variation of an established gene pool.
Macroevolution: changes that occur at or above the level of species. While microevolution can be readily applied to the study of individual
species and can be aimed prospectively to predict allele frequencies, and to some extent evolutionary outcomes within a population,
microevolution alone is insufficient to explain large-scale changes across multiple populations and geological time scales. Retrospective
studies aimed at understanding the origins of genes, genomes and by extension species and phyla are, instead, the domain of
macroevolution. Although most, if not all, of the microevolutionary causes that drive variation within a species apply to macroevolution [74],
the fundamental difference between them is scale. Rather than looking within a species and within that species’ lifetime, macroevolution
focuses on the general forces driving the evolution of species across millions of years. Disciplines such as paleontology [75], comparative
genomics [76–78], evolutionary developmental biology [79], and more recently genomic phylostratigraphy [27,80,81], contribute the lion’s
share of evidence for macroevolution.
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R773geographic ecosystem variation [20]. Thus, understanding
first principles of how variation is introduced into a popula-
tion of either cells or animals that allow measurements of
mutation, selection, genetic drift and flow can, in principle,
inform essential aspects of cancer biology, such as the
sequence of events that lead to the progression of a tumor,
or whether a given mutation does or does not provide a pro-
liferative (reproductive) advantage to a cancerous cell, and
most importantly, help predict the outcomes of artificial
selection (therapeutic intervention) such as resistance to
chemotherapy.
Macroevolution and the Force of Retrospection
Studies of macroevolutionary transitions (Box 1) can
illuminate the emergence of species and variation acrossA
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Figure 1. Microevolutionary variation in
human tumors and butterflies.
(A) A representative pattern for common,
solid cancers. Selective pressures allow some
mutant subclones to expand while others
become extinct or remain dormant. Vertical
lines represent restraints or selective pres-
sures. Adapted from [7]. (B) Morphological
diversity of wing patterns inHeliconius butter-
flies [64]. Recent molecular evidence shows
that the many adaptive multi-locus poly-
morphisms seen in this butterfly arise from
chromosomal reorganization of a co-adaptive
gene set found in a chromosomal interval of
about 400 kb [19].and within taxa. When new attributes such as multi-
cellularity emerge allowing organisms to venture into new
environments, adaptive radiations follow, provided they
encounter little or no competition [21,22]. Interestingly,
multicellularity has been associated with the evolutionary
appearance of genes known to be involved in tumor
formation in humans. It has been proposed that cancer in
humans is an evolutionary legacy [23,24]. Yet, studies on
whether tumors can form in basal animals have not been
extensive [25,26]. Moreover, given the remarkable differ-
ences between the molecular nature of tumor suppressors
in invertebrates, such as Drosophila melanogaster, and
vertebrates, such as humans and mice [5], the formal possi-
bility remains that genes responsible for cancer may have
emerged independently through convergent evolution.Tx
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Figure 2. Phylostratigraphic map of cancer genes.
The log-odds statistics of documented human cancer genes in four
different databases are illustrated on the y-axis. Positive values denote
over-representation, while negative values indicate under-representa-
tion. The x-axis values indicate phylogenetic transitions, with ‘1’ repre-
senting the origin of the first cells and ‘5’ representing the transition
from single-celled to multicellular organisms. (Adapted and repro-
duced with permission from Domazet-Lozo and Tautz [27].) The
colored arrows indicate significant over-representation of cancer
genes at these specific phylogenetic positions (for a complete list of
the phylostrata positions please consult [27]).
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for reconstructing macroevolutionary trends — of genes
that whenmutated are thought to participate in tumor forma-
tion and development, however, is beginning to provide
robust macroevolutionary evidence for the ancient origins
of cancer [27].
Comparison of the human cancer genes deposited in four
databases (COSMIC [28], Entrez section in CancerGenes,
CancerGenes proper [29] and Network of Cancer Genes
[30]) against the genome sequences of organisms arranged
according to their phylogenetic relationships uncovered
a clear, statistically significant relationship between the likely
point of emergence of metazoans and the appearance of
genes we presently associate with cancer [27]. It is remark-
able that in the transition between Holozoa (represented by
the unicellular choanoflagelates) and early metazoans (rep-
resented by poriferans), there is a statistically significant
overrepresentation of the genes found in the four cancer
databases (Figure 2). Whether these genes are involved in
tumor suppression and/or formation in these organisms
remains largely unknown, but as we will see below, evidence
from functional studies of invertebrates, such as the
planarian Schmidtea mediterranea, are beginning to illumi-
nate this question [2,4]. If, as the macroevolutionary evi-
dence suggests, the genes that cause cancer today have
an ancient evolutionary origin, it becomes clear that our
present reliance on about a handful of model systems from
only two branches of the animal tree of life (Deuterostomes
and Ecdysozoans) may be severely limiting our ability tomechanistically understand cancer and many other human
diseases.
Development and Heritable Variation
While microevolution can tell us much about relatively rapid
changeswithin a population, andmacroevolution illuminates
the slow changes at or above the species level, develop-
mental biology allows us to understand individuals. From
the very moment an egg is fertilized, through its gastrulation,
growth, maturity and death, development provides the
context in which genes and the environment interact to pro-
duce all individuals in any given population. Hence, nowhere
are the intertwined threads of microevolution, macroevolu-
tion and the environment more saliently displayed than
during development. Evolutionary and developmental biolo-
gists follow development to understand the history, function
and malfunctions of the individual. This approach, however,
took nearly a hundred years to mature. Confronted with
a myriad of developmental strategies used by embryos to
become fully grown animals (Figure 3A), developmental biol-
ogists in the late 19th century such as August Weismann [31]
and T.H. Morgan [32] postulated that biological diversity
arises from changes in gene functions, while evolutionary
biologists like Bateson would argue that the selection of
variation [33] was, in fact, truly responsible for the diversity
found in biological systems [34]. Such explanatory dispar-
ities arose from analyzing the same problem (heritable varia-
tion) from different levels of analysis (genes vs. adaptations),
and yielded many unproductive debates [35]. Resolving this
quandarywould require first a synthesis ofmeiosis, recombi-
nation and genetics, and the advent of molecular biology
(Figure 3B). This integrative approach, in turn, has allowed
developmental biologists to launch an unprecedented ex-
ploration of development and evolution at multiple levels of
analysis that has resulted in and continues to yield spectac-
ular insights into our understanding of life.
Developmental genetics also has identified genes that can
cause sudden changes in adult morphology [36], and thus
are capable of introducing phenotypic variation into a popu-
lation [37]. Hence, much effort has been invested in recent
years to understand the functional relationships among
genes, and between genes and the environment in develop-
mental systems. As these functional relationships begin to
emerge, it is becoming quite clear that, at any time during
the life of an organism, a single gene can participate in count-
less regulatory events [38]. Such complexity is robustly sup-
ported by the work on gene regulatory networks (GRNs) that
have been defined based on studies of sea urchin embryo-
genesis (Figure 3C). The application of this methodology to
both sea urchin andDrosophila embryogenesis, for example,
has revealed that mutations affecting cis-regulatory nodes
of a GRN are associated with the gain, loss, or co-option of
regulatory genes, which then may alter the architecture of
a GRN and change developmental outcomes [39–42].
In some ways, the state of cancer research today can be
likened to the state in which developmental biology found
itself at the beginning of the 20th century: disparate explana-
tions arising from different levels of analysis which are
hard to reconcile in the absence of an integrative approach.
Therefore, efforts to understand a disease as complex as
cancer at the dawn of the 21st century by only looking at
the genes that cause it, without taking into consideration
micro- and macroevolutionary forces, should strike us as
incomplete. It should also be readily apparent that the
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Figure 3. Developmental biology and the
study of variation.
(A) Diversity of embryonic developmental
strategies displayed (clockwise) by: polar
lobe extrusion (p3) in a vegetative view of the
marine scaphopod mollusk Dentalium em-
bryo (adapted from [65]); invariant lineages
of the cephalopod endosymbiont dycemid
mesozoan embryo (adapted from [66]); rear
view of a 6 hour 15 min Nereis embryo
(a marine, polychaete worm) depicting cell
lineages of the various blastomeres [67]);
chromosome diminution in Ascaris embryos
(small fragments in division plane, large
blastomere, middle) as described by Theodor
Boveri in 1910 [68] (images kindly supplied
by Dr J.G. Gall). (B) Cyril Darlington’s schema
integrating fertilization, recombination and
genetics to explain the connection between
genetics and the physical entity of chromo-
somes (adapted from [69]). (C) The most
recent gene regulatory network of sea
urchin primary mesenchyme cells (PMCs) at
6–30 hours of development [70].
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R775regulatory networks associated with
so-called cancer genes need to be
elucidated both under normal physio-
logical conditions across the entire
gamut of development as well as
disease states in multiple model systems. Otherwise, a likely
outcome for the biomedical sciences will be to repeat history
and engage in unproductive debates about the cause of
disease not too different from those held by biologists at
the beginning of the 20th century about the nature of varia-
tion. More than ever, the causes of health and disease
need to be looked at through analyses at multiple levels of
inquiry.
P53 and the Evolution of Tumor Suppression
Cellular proliferation needs to be regulated to ensure the
survival of multicellular organisms, and therefore, mecha-
nisms for regulating tumor suppression are likely to have
ancestral evolutionary origins. Yet, the vast efforts invested
in understanding protein functions alone as a means to
discover therapeutic targets to combat cancer has skewed
current thinking on the biology of tumor suppression.
PTEN, P53 and RB — the three tumor suppressor proteins
most commonly mutated in human tumors [43] — are not
tumor suppressors in invertebrate model systems such as
Drosophila and C. elegans, and the genes acting as tumor
suppressors in the fly (e.g., scribbled, lethal giant larvae,
discs large) do not appear to be tumor suppressors in
mammals [44–47]. Therefore, it has becomewidely accepted
that the tumor suppression functions of proteins such as
P53 may have arisen recently in mammalian evolution from
an ancestral role of this protein in DNA-damage sensing or
DNA repair [48].
Moreover, the differences in life-span and size between
the model invertebrate and vertebrate model systems used
to study tumor suppression do not help to simplify matters.
Take Peto’s paradox, for example [49], which essentially
states that if all mammalian cells are equally susceptible to
oncogenic mutations and have equivalent tumor suppres-
sion capacities, then the number of cells that can becomemalignant in a given organismwould be directly proportional
to the number of cells and life-span of the organism. In other
words, under these conditions the probability of a blue whale
living a cancer-free life would be less than w2.27 3 10253
[50]. However, cancer incidence does not scale with body
size or longevity across species [50,51]. If it did, whales
would die before they could reproduce and thus would
have become extinct long ago [52]. Becausemammals alone
can differ close to a million-fold in size [51] and a hundred-
fold in maximum life span [53], the obvious issue raised by
Peto’s paradox is that large, long-lived animals such as
whales and elephants are suppressing tumors much more
efficiently than we humans are.
Given that all biological attributes arise from micro- and
macroevolutionary trends on the one hand, and through
interactions between genes and the environment during
development on the other, why should tumor suppression
be exempt from these forces? The perplexing differences
in the functions and numbers of proteins functioning as
tumor suppressors in different animals likely reflect a
tortuous evolutionary history for these molecules across
different phyla. The paleostratigraphic data (Figure 2) clearly
indicate that many of our simpler multicellular ancestors
already possessed a large cohort of genes which can be as-
sociated with cancer [27]. In fact, the closest unicellular rela-
tive to multicellular animals, the choanoflagellate Monosiga
brevicollis, has a homolog to both p53 and p63 (Figure 4A).
If, as generally believed, p53 acquired its tumor suppression
function in vertebrates [48], and also became duplicated in
vertebrates to control stem cell self-renewal [54], what could
the function of this family of proteins be in a unicellular
organism? These types of macroevolutionary analyses
highlight two very important points. First, dissecting the
functions of the p53 family of proteins in a single-celled
animal such as Monosiga promises to be immensely
Figure 4. P53 and tumor suppression in
planarians.
(A) Phylogenetic tree of the Metazoa, high-
lighting the number, family members and
functions of P53 and PTEN (adapted from
[5]). TSG: tumor suppressor gene. (B) The
planarian Schmidtea mediterranea. Scale
bar: 200 mm. (C) Smed-p53(RNAi) causes
hyperproliferation (blue line) and reveals the
tumor suppression function of this molecule
in planarians. Mitotic figures are visualized
using themarker H3ser10p, whichmarks cells
during the G2/M transition of the cell cycle.
Normal and hyperproliferatrion shown in
representative animals on the left. Loss of
cell division at the latest time point shown
by representative animals at right. Statistical
differences: Student’s t-test. Error bars are
SEM. Scale bars: 100 mm. (D) Cross-sections
of control and RNAi-treated animals. Dorsal
on top. Smed-p53(RNAi) causes an increase
in numbers in stem cells (Smedwi-1, arrow-
head) and cell proliferation (PCNA, arrow-
head), and a concomitant decrease in the
number of progenitor cells (NB21.11e, arrow-
head). (C) and (D) modified from [4].
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tumor suppressor activity of these proteins. Determining
what roles p53 and/or p63 may play in the proliferation and
formation of colonies in choanoflagelates, for instance,
should provide mechanistic insight into the normal, phys-
iological, and ancestral functions possessed by these
proteins. And second, a better understanding of cancer
suppression mechanisms necessitates the mechanistic
interrogation of a much more evolutionarily diverse cohort
of organisms than those being currently investigated.
Until recently, there has been no functional study of a p53
family member in an invertebrate that has very high require-
ments for adult tumor suppression, nor of a member of
the Lophotrochozoa (Figure 4A). One such organism is the
planarian Schmidtea mediterranea (Figure 4B), because of
its remarkable developmental plasticity a model system
for stem cell biology, regeneration and tissue homeostasis
[55]. S. mediterranea has a single p53 homolog called
Smed-p53, whose expression is largely restricted to the
newly made progeny of stem cells [4] (Figure 4B). RNAi of
Smed-p53 results in an increase in stem cell number and
proliferation at the expense of daughter cell differentiation,
consistent with Smed-p53 having tumor suppressor-like
function in planarians (Figure 4C). Moreover, as the Smed-
p53 loss-of-function phenotype progresses, a terminal
depletion of the stem cell population is observed, suggesting
that this molecule may also function similarly to vertebrate
p63. Smed-p53 is the first invertebrate p53-family member
shown to have a role in stem cell proliferation control, self-
renewal and lineage specification. Altogether, these studies
support the conclusion that an ancestral p53-family member
was already functioning in stem cell biology and prolifera-
tion control, and that these functions were not vertebrate
inventions. Furthermore, it is interesting to note thatplanarian P53 and other vertebrate
tumor suppressor proteins such as
PTEN [2] are involved in this organism’s
ability to temporarily allow their stemcells to hyper-proliferate after injury. Such activity raises
the very intriguing possibility that what we refer to as tumor
suppression may simply be an ancestral molecular mecha-
nism responsible for surveying changes in the environment
(i.e., loss of tissues to amputation) in order to orchestrate
the appropriate proliferative and cellular differentiation
responses required by such changes (i.e., wound repair
and regeneration). Participation in such physiological repair
mechanisms may in fact be the main, evolutionarily selected
function of tumor suppressors in vertebrates.
Conclusion
The notion that complex diseases, such as cancer, may
have ancient evolutionary origins opens the door to the
exploration of this problem in evolutionarily diverse organ-
isms. By studying animals, such as planarians, in which
gene function can be readily perturbed in the adult condition
(thus bypassing embryonic lethality), it should be possible
to test multiple hypotheses in a relatively short period
of time and hence spur the discovery of fundamental, evolu-
tionarily conserved mechanisms not only underpinn-
ing diseases associated with hyperproliferation, such as
cancer, but also mechanisms that modulate cell prolifera-
tion during biological processes such as regeneration and
degeneration.
Equally, if not more importantly, all such studies aimed
at understanding complex biological functions and mal-
functions must integrate a synthesis of microevolution,
macroevolution, genetics and developmental biology. For
instance, a re-examination under this light of the mammalian
model systems presently used to study human disease
seems warranted. Given the effects that inbreeding, artificial
selection and the environment can have on organisms in as
little as one generation, such conditions ultimately become
Special Issue
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under standard laboratory conditions are generally seden-
tary, have constant access to food, are provided with little
to no stimulation and have been shown to be metabolically
morbid [56,57]. In studies of tumor induction, standard
control rodents were shown to develop more spontaneous
tumors than mice that ate less [58,59]. Thus, experiments
in which such mice are used as controls will confound the
analyses of essential aspects of cancer biology such as the
correct elucidation of the sequence of events that lead to
the progression of the disease, or whether a given mutation
does or does not provide a proliferative advantage to a
cancerous cell. More alarmingly, such mice can negatively
skew the outcomes of therapeutic interventions, and nega-
tively affect outcome predictions of human studies. The
fact that the vast majority of cancer drugs tested in over
500 phase II clinical trials and shown to be effective in
preclinical standard rodent models proved ineffective in
humans should make us take pause [60].
Finally, given Peto’s paradox, rather than looking atmouse
models with a high predisposition to cancer, would it not be
equally important to look at mouse strains that may be,
in fact, resistant to cancer? Mouse species of feral origins
such as Mus spretus and Mus castaneus have been re-
ported to have low tumor incidence [61], and F1 hybrids of
M. spretus and Mus musculus tolerated chemical carcino-
genesis protocols, and failed to develop tumors in most
tissues tested [62]. Understanding the genetic composition
of such variation in the mouse population, and the GRNs
associated with this apparent resistance to cancer should
help determine the extent to which tumor inhibition is regu-
lated by microevolutionary and/or developmental forces.
Alternatively, would it not be beneficial for studies of tumor
suppression to develop cell lines from elephants, whose
genome appears to contain at least 12 copies of p53? In
sum, if human health and disease are to cease perplexing
us, it seems unavoidable that understanding their respective
causes necessitates both retrospective and prospective bio-
logical studies, an effort that will require continued research
with established model organisms [63], the development of
numerous, evolutionarily diverse model systems, and the
simultaneous deployment of multiple disciplines at multiple
levels of inquiry.Acknowledgements
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